HIV-1 Infections Clinical Trial
Official title:
A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects
The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.
Despite the remarkable strides made in the treatment of HIV-1-infected persons over the last
decade, current first-line ART regimens are imperfect. The ideal combination, unlike some
current first-line options, would have uncompromised efficacy in the presence of transmitted
drug-resistant variants. The primary purpose of this study is to estimate the cumulative
proportion of ART-naive participants experiencing virologic failure at or prior to week 24
after initiating raltegravir (RAL) plus darunavir/ritonavir (DRV/RTV).
The study will last 52 weeks. All participants will follow the same treatment schedule and
take RAL plus DRV/RTV orally daily for the duration of the trial.
After entry, all participants will have scheduled visits at weeks 1, 4, 12, 24, 36, 48, and
52. Medical/medication history, blood and urine collection, and liver function tests will
occur at screening. A targeted physical exam and concomitant medications history will occur
at all study visits. Blood and urine collection and liver function tests will occur at most
study visits. For females, a pregnancy test will occur at screening and study entry.
RAL and DRV were provided by the study. RTV was not provided by the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01013415 -
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
|
Phase 1 | |
Active, not recruiting |
NCT02923713 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
Completed |
NCT01151319 -
Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults
|
Phase 1 | |
Completed |
NCT01138605 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
Completed |
NCT01078233 -
Observational Data Analysis in EuroSIDA (MK-0518-058)
|
||
Recruiting |
NCT02593409 -
HIV PrEP Priming of Immune Effectors
|
Phase 4 | |
Completed |
NCT00557245 -
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
|
Phase 3 | |
Withdrawn |
NCT00984152 -
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
|
Phase 3 | |
Completed |
NCT00799058 -
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
|
Phase 1/Phase 2 | |
Completed |
NCT01159275 -
Lopinavir (LPV) Dose Reduction
|
Phase 1/Phase 2 | |
Completed |
NCT01281813 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
Completed |
NCT01078246 -
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
|
||
Active, not recruiting |
NCT03027297 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
Completed |
NCT01139905 -
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
|
Phase 2 | |
Completed |
NCT01033760 -
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
|
Phase 3 | |
Completed |
NCT01074931 -
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
|
N/A |